Intergroupe Francophone Du Myelome
Intergroupe Francophone Du Myelome (IFM) is a prominent organisation headquartered in France, dedicated to advancing research and treatment in the field of multiple myeloma. Founded in the early 2000s, IFM has established itself as a leader in the oncology sector, focusing on collaborative clinical trials and innovative therapeutic strategies. With a strong presence across Francophone regions, IFM is committed to improving patient outcomes through its unique approach to myeloma research and treatment. The organisation's core services include the development of clinical guidelines and the facilitation of international collaborations, which have significantly contributed to its reputation in the medical community. Notable achievements include numerous successful clinical trials that have paved the way for new treatment options, solidifying IFM's position as a key player in the fight against multiple myeloma.
DitchCarbon Score
How does Intergroupe Francophone Du Myelome's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Intergroupe Francophone Du Myelome's score of 6 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Intergroupe Francophone Du Myelome's reported carbon emissions
Intergroupe Francophone Du Myelome, headquartered in France, currently does not have available emissions data for recent years, as no specific figures have been provided. Consequently, there are no reported carbon emissions in kg CO2e, nor are there any established reduction targets or climate pledges outlined in their initiatives. In the absence of concrete data, it is essential to note that many organisations in the healthcare sector are increasingly focusing on sustainability and climate commitments. This includes setting science-based targets for emissions reductions and engaging in initiatives aimed at minimising their carbon footprint. As the industry evolves, Intergroupe Francophone Du Myelome may consider adopting similar strategies to enhance their environmental responsibility and contribute to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Intergroupe Francophone Du Myelome is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
